Skip to content

Study · Not a test of the peptide alone · 2025

8 results

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.

Demogeot N, Sargos P, Salleron J, Guérif S, de Crevoisier R, Calais G, Hannoun-Levi JM, Bouché G, Hennequin C, Cretin J, Sahki N, Marchesi V and 10 more

Show all authors

Belkacemi Y, Khalifa J, Azria D, Bauer N, Pommier P, Simon JM, Léger C, Beckendorf V, Dubray B, Supiot S

European urology14 Aug 2025Cited by 1 (Europe PMC)

PMID40816927 (opens in a new tab)DOI10.1016/j.eururo.2025.07.019 (opens in a new tab)PepBankPUB-40816927
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

Background and objectiveFew studies have compared short-term androgen deprivation (STADT) combined with high-dose radiotherapy (STADT-RT) versus high-dose radiotherapy (RT) alone in localized prostate cancer.MethodsThe GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT. Disease-free survival (DFS) was the primary endpoint. Secondary endpoints were overall survival (OS), biochemical failure (BF), metastasis failure (MF), toxicity, and quality of life.Key findings and limitationsAmong the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer. At median follow-up among surviving patients of 84 mo (interquartile range 62-99 mo), the 5-yr DFS rate was 76% in RT arm versus 84% in STADT-RT arm (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.43-0.94]). ADT addition decreased BF (HR 0.45, 95% CI 0.28-0.72) and MF (HR 0.5, 95% CI 0.23-1.11) but not OS (HR 1.22, 95% CI 0.65-2.29). There were no significant differences for RT versus STADT-RT in the incidence rates for grade ≥2 toxicity in terms of acute gastrointestinal (GI) toxicity (26%, 95% CI 20-32 vs 26%, 95% CI 20-33), acute genitourinary (GU) toxicity (39%, 95% CI 32-46% vs 42%, 95% CI 35-50%), late GI toxicity (21%, 95% CI 16-28% vs 23%, 95% CI 18-30%), or late GU toxicity (30%, 95% CI 24-38% vs 27%, 95% CI 21-34%).Conclusions and clinical implicationsSTADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In patients with localized prostate cancer, triptorelin plus flutamide and radiotherapy improved disease-free survival versus radiotherapy alone.

    In plain wordsIn patients with localized prostate cancer, triptorelin plus flutamide and radiotherapy improved disease-free survival versus radiotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseDisease-free survival
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Disease-free survival
    84%
    STADT-RT at 5 years
    Disease-free survival
    76%
    RT at 5 years
    Disease-free survival hazard ratio
    0.64 ratio
    STADT-RT versus RT

    Source sentences

    Summary
    At median follow-up among surviving patients of 84 mo (interquartile range 62-99 mo), the 5-yr DFS rate was 76% in RT arm versus 84% in STADT-RT arm (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.43-0.94]).
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In patients with localized prostate cancer, triptorelin plus flutamide and radiotherapy reduced biochemical failure versus radiotherapy alone.

    In plain wordsIn patients with localized prostate cancer, triptorelin plus flutamide and radiotherapy reduced biochemical failure versus radiotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseBiochemical failure
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Biochemical failure hazard ratio
    0.45 ratio
    STADT-RT versus RT

    Source sentences

    Summary
    ADT addition decreased BF (HR 0.45, 95% CI 0.28-0.72) and MF (HR 0.5, 95% CI 0.23-1.11) but not OS (HR 1.22, 95% CI 0.65-2.29).
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In patients with localized prostate cancer, metastasis failure was lower with triptorelin/flutamide plus radiotherapy, but its confidence interval included no difference.

    In plain wordsIn patients with localized prostate cancer, metastasis failure was lower with triptorelin/flutamide plus radiotherapy, but the confidence interval included no difference.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMetastasis failure
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Metastasis failure hazard ratio
    0.5 ratio
    STADT-RT versus RT

    Source sentences

    Summary
    ADT addition decreased BF (HR 0.45, 95% CI 0.28-0.72) and MF (HR 0.5, 95% CI 0.23-1.11) but not OS (HR 1.22, 95% CI 0.65-2.29).
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In patients with localized prostate cancer, triptorelin plus flutamide and radiotherapy did not improve overall survival versus radiotherapy alone.

    In plain wordsIn patients with localized prostate cancer, triptorelin plus flutamide and radiotherapy did not improve overall survival versus radiotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOverall survival
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Overall survival hazard ratio
    1.22 ratio
    STADT-RT versus RT

    Source sentences

    Summary
    ADT addition decreased BF (HR 0.45, 95% CI 0.28-0.72) and MF (HR 0.5, 95% CI 0.23-1.11) but not OS (HR 1.22, 95% CI 0.65-2.29).
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In patients with prostate cancer, grade ≥2 acute gastrointestinal toxicity did not differ significantly between triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    In plain wordsIn patients with prostate cancer, grade ≥2 acute gastrointestinal toxicity was similar with triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeAcute gastrointestinal toxicity
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Grade ≥2 acute GI toxicity incidence
    26%
    RT alone
    Grade ≥2 acute GI toxicity incidence
    26%
    STADT-RT

    Source sentences

    Summary
    There were no significant differences for RT versus STADT-RT in the incidence rates for grade ≥2 toxicity in terms of acute gastrointestinal (GI) toxicity (26%, 95% CI 20-32 vs 26%, 95% CI 20-33)
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  6. 06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In patients with prostate cancer, grade ≥2 acute genitourinary toxicity did not differ significantly between triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    In plain wordsIn patients with prostate cancer, grade ≥2 acute genitourinary toxicity was similar with triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeAcute genitourinary toxicity
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Secondary
    Outcome group
    Adverse events · Kidney and urinary

    Measurements

    Grade ≥2 acute GU toxicity incidence
    39%
    RT alone
    Grade ≥2 acute GU toxicity incidence
    42%
    STADT-RT

    Source sentences

    Summary
    acute genitourinary (GU) toxicity (39%, 95% CI 32-46% vs 42%, 95% CI 35-50%)
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  7. 07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In patients with prostate cancer, grade ≥2 late gastrointestinal toxicity did not differ significantly between triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    In plain wordsIn patients with prostate cancer, grade ≥2 late gastrointestinal toxicity was similar with triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeLate gastrointestinal toxicity
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Grade ≥2 late GI toxicity incidence
    21%
    RT alone
    Grade ≥2 late GI toxicity incidence
    23%
    STADT-RT

    Source sentences

    Summary
    late GI toxicity (21%, 95% CI 16-28% vs 23%, 95% CI 18-30%)
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  8. 08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In patients with prostate cancer, grade ≥2 late genitourinary toxicity did not differ significantly between triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    In plain wordsIn patients with prostate cancer, grade ≥2 late genitourinary toxicity was similar with triptorelin/flutamide plus radiotherapy and radiotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeLate genitourinary toxicity
    Study

    n = 370

    Comparator
    radiotherapy alone
    Analysis
    Secondary
    Outcome group
    Adverse events · Kidney and urinary

    Measurements

    Grade ≥2 late GU toxicity incidence
    30%
    RT alone
    Grade ≥2 late GU toxicity incidence
    27%
    STADT-RT

    Source sentences

    Summary
    or late GU toxicity (30%, 95% CI 24-38% vs 27%, 95% CI 21-34%).
    2 context sentences
    Summary · context
    The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT.
    Summary · context
    Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.